116 related articles for article (PubMed ID: 19698272)
21. Multiple myeloma maintenance therapy: a review of the pharmacologic treatment.
Shank BR; Brown VT; Schwartz RN
J Oncol Pharm Pract; 2015 Feb; 21(1):36-51. PubMed ID: 24395544
[TBL] [Abstract][Full Text] [Related]
22. Multiple myeloma: chemotherapy or transplantation in the era of new drugs.
Palumbo A; Rajkumar SV
Eur J Haematol; 2010 May; 84(5):379-90. PubMed ID: 20345446
[TBL] [Abstract][Full Text] [Related]
23. [Therapy of multiple myeloma and its complications].
Avvisati G; Pulsoni A; Petrucci MT; Tribalto M
Recenti Prog Med; 1990 Oct; 81(10):642-50. PubMed ID: 2291008
[TBL] [Abstract][Full Text] [Related]
24. Role of thalidomide in the treatment of patients with multiple myeloma.
Morgan GJ; Davies FE
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S14-22. PubMed ID: 23827438
[TBL] [Abstract][Full Text] [Related]
25. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
26. [Role of interferon in the treatment of multiple myeloma].
Shimazaki C
Nihon Rinsho; 2006 Jul; 64(7):1291-6. PubMed ID: 16838647
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
28. Evolving role of stem cell transplantation in multiple myeloma.
Harousseau JL; Moreau P
Clin Lymphoma Myeloma; 2005 Sep; 6(2):89-95. PubMed ID: 16231846
[TBL] [Abstract][Full Text] [Related]
29. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
[TBL] [Abstract][Full Text] [Related]
30. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
Björkstrand B; Svensson H; Goldschmidt H; Ljungman P; Apperley J; Mandelli F; Marcus R; Boogaerts M; Alegre A; Remes K; Cornelissen JJ; Bladé J; Lenhoff S; Iriondo A; Carlson K; Volin L; Littlewood T; Goldstone AH; San Miguel J; Schattenberg A; Gahrton G
Bone Marrow Transplant; 2001 Mar; 27(5):511-5. PubMed ID: 11313685
[TBL] [Abstract][Full Text] [Related]
31. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.
Maiolino A; Hungria VT; Garnica M; Oliveira-Duarte G; Oliveira LC; Mercante DR; Miranda EC; Quero AA; Peres AL; Barros JC; Tanaka P; Magalhães RP; Rego EM; Lorand-Metze I; Lima CS; Renault IZ; Braggio E; Chiattone C; Nucci M; de Souza CA;
Am J Hematol; 2012 Oct; 87(10):948-52. PubMed ID: 22730113
[TBL] [Abstract][Full Text] [Related]
32. Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
Chang WJ; Kang ES; Lee ST; Kim SH; Kim DW; Kim SJ; Kim K
Acta Haematol; 2014; 132(2):226-32. PubMed ID: 24732093
[TBL] [Abstract][Full Text] [Related]
33. ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma.
Offidani M; Leoni P; Corvatta L; Polloni C; Gentili S; Savini A; Alesiani F; Brunori M; Catarini M; Visani G; Samori A; Burattini M; Centurioni R; Montanari M; Fraticelli P; Ruggieri M; Falcioni S; Galieni P
Eur J Haematol; 2010 Jun; 84(6):474-83. PubMed ID: 20331733
[TBL] [Abstract][Full Text] [Related]
34. Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?
Bladé J; Esteve J
Med Oncol; 2000 May; 17(2):77-84. PubMed ID: 10871813
[TBL] [Abstract][Full Text] [Related]
35. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma.
Cogle CR; Moreb JS; Leather HL; Finiewicz KJ; Khan SA; Reddy VS; Wingard JR
Am J Hematol; 2003 Jul; 73(3):169-75. PubMed ID: 12827653
[TBL] [Abstract][Full Text] [Related]
36. An old drug with a new future: bendamustine in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Vigna E; Martino M; Morabito L; Lucia E; Bossio S; De Stefano L; Granata T; Palummo A; Morabito F
Expert Opin Pharmacother; 2013 Nov; 14(16):2263-80. PubMed ID: 24053161
[TBL] [Abstract][Full Text] [Related]
37. Maintenance therapy for multiple myeloma with particular emphasis on thalidomide.
Dürk HA
Onkologie; 2006 Dec; 29(12):582-90. PubMed ID: 17202830
[TBL] [Abstract][Full Text] [Related]
38. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
Kyle RA
Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
[TBL] [Abstract][Full Text] [Related]
39. [Maintenance therapies of thalidomine and interferon-α in multiple myeloma].
Li J; Cai JH; Huang BH; Liu JR; Zheng D
Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(48):3417-20. PubMed ID: 22333255
[TBL] [Abstract][Full Text] [Related]
40. Thalidomide maintenance in multiple myeloma: certainties and controversies.
Cavo M; Pantani L; Tacchetti P; Pallotti MC; Brioli A; Petrucci A; Zamagni E; Tosi P
J Clin Oncol; 2009 Nov; 27(32):e186-7; author reply e188. PubMed ID: 19770366
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]